BioHive

What BioHive does

BioHive SAS is a French biotechnology company founded in 2023 and headquartered at Genopole Campus 3 in Évry-Courcouronnes, France. The company develops iPSc-derived skin organoid technology — advanced in vitro skin models incorporating multiple cell types (epidermis, dermis, hair follicles, neurons, and adipocytes) — for use in pharmaceutical and dermo-cosmetic R&D. Its core product platform enables customizable organoid biobanking, disease modeling of genetic and inflammatory skin conditions, and tailored research services including toxicity-efficacy analysis, cell/cell interaction studies, inflammatory signature analysis, and 3D imaging.

The company operates a sales-led go-to-market motion targeting pharmaceutical and dermo-cosmetic companies through direct email outreach, demo booking, and downloadable technical resources (catalogs, application notes, posters). BioHive has secured a Golden Ticket award at Amgen's BioLabs location in January 2025 and maintains a scientific partnership with Sanofi through the Sanofi IDEA iTech initiative. The company is supported by French biotech ecosystem partners including Genopole, Bpifrance Le Hub, Medicen, and BioValley France.

The team consists of three founders: Cécile Naït (PhD, Co-founder & CEO), Cesare Massart (Late-founder & COO), and Giulia Ferri (PhD in Molecular and Cellular Biology, CTO). The company offers quote-based pricing on multi-year contracts for research services, with no publicly disclosed pricing, revenue figures, or external funding rounds. BioHive is a privately held French SAS (Société par Actions Simplifiée) with founder ownership.

Name

BioHive

Legal name

BioHive SAS

Website

https://biohive-innovations.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

BioHive is a French biotech startup developing iPSc-derived skin organoids — customizable multi-cell-type in vitro skin models — for toxicity and efficacy testing in pharmaceutical and dermo-cosmetic R&D, with tailor-made research services and a partnership with Sanofi.

Ownership category

akta.pro rank

Product category

In Vitro Skin Organoid Models

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industries

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), Cell-Based & Potency Assays (Bioassays) (HLAGADAH)

Keywords

• Skin organoid models
• In vitro skin testing
• Pharmaceutical research services
• Dermo-cosmetic testing
• Toxicity efficacy analysis

Headquarters

HQ city

Évry

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Research services (toxicity-efficacy analysis): Tailor-made research services for pharmaceutical and dermo-cosmetic industries including toxicity-efficacy analysis, cell/cell interactions, inflammatory signature analysis, and 3D imaging. Services provided to pharmaceutical companies for screening, efficacy and toxicity analysis, and pathology-specific models.
2. Organoid technology catalog/products: Customizable skin organoid products and technology catalog available through one-pagers and application notes. Products include organoid models for hair & scalp, longevity, and neurocosmetics research.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

BioHive develops and supplies customizable iPSc-derived skin organoid models that include multiple cell types (epidermis, dermis, hair follicles, neurons, and adipocytes), and provides tailor-made contract research services for compound analysis. The core services include toxicity-efficacy analysis, cell/cell interaction studies, inflammatory signature profiling, and 3D imaging for pharmaceutical and dermo-cosmetic R&D programs, supported by a customizable organoid biobank for disease modeling.

Product overview

BioHive offers a unified product platform centered on Skin Organoids—a customizable in vitro skin model technology. The platform provides biobank access to organoids that can be fine-tuned to suit specific biological needs, supporting disease modeling of genetic and inflammatory conditions. Services include toxicity-efficacy analysis, cell/cell interaction studies, inflammatory signature analysis, and 3D imaging. The offering serves both pharmaceutical and dermo-cosmetic industries, with tailored solutions for screening, efficacy testing, and pathology-specific models.

Differentiator

Problem solved

Functional benefit

Products and services

• Skin Organoids iPSc-derived in vitro skin models featuring multiple cell types (epidermis, dermis, hair follicles, neurons, adipocytes), offering an unlimited cell source with high reproducibility. Sold as customizable organoid products for pharmaceutical and dermo-cosmetic R&D programs.
• Tailor-made Skin Compound Research Services Custom contract research services for skin compound analysis including toxicity-efficacy analysis, cell/cell interaction studies, inflammatory signature profiling, and 3D imaging. Targeted at pharmaceutical and dermo-cosmetic companies seeking tailored in vitro testing and pathology-specific models.

Quantifiable outcome

• Reduces pharmaceutical R&D costs by 25%
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Amgen / BioLabscoreStrategic or Co-development Partner · 1 January 2025BioHive was awarded Golden Ticket at Amgen's Biolabs location, recognizing the company as one of the innovative biotech startups laureates. Biolabs is a coworking and lab space network for biotech startups.
• SanoficoreStrategic or Co-development PartnerSanofi logo appears in the Our Partners section with reference to the Sanofi IDEA iTech initiative (Scientific Relations and Initiatives in Europe). This indicates a scientific collaboration or partnership in research and development.
• GenopolecoreStrategic or Co-development PartnerBioHive is located at Genopole Campus 3, France's leading biotech cluster. Genopole is a strategic partner providing the ecosystem and infrastructure for biotech innovation.
• MedicenminorStrategic or Co-development PartnerMedicen Paris Region logo appears in partners section. Medicen is a competitiveness cluster for innovative health technologies in the Paris region.
• BioValley FranceminorStrategic or Co-development PartnerBioValley France logo appears in partners section. BioValley France is a life sciences cluster supporting networking and events for biotech companies.
• IPHDminorOthersIPHD logo appears in partners section. IPHD appears to be an academic or research institution partnership.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Emulate: Emulate develops organ-on-chip technology with primary-cell-based tissue models used by pharma and consumer-products companies for preclinical testing. Its platform overlaps with BioHive in offering in vitro tissue models for compound efficacy and safety assessment.
• Episkin (L'Oréal): Episkin, a subsidiary of L'Oréal, manufactures reconstructed human skin models for cosmetic and pharmaceutical testing. It is one of the most established players in the exact same product category BioHive targets with its iPSc-derived organoid platform.
• Phenion (Henkel): Phenion, part of Henkel, develops 3D skin models and offers testing services for cosmetics, personal care, and pharmaceutical customers. It competes head-to-head with BioHive in in vitro skin compound analysis and is integrated into a major consumer-products R&D organization.
• TissUse: TissUse builds multi-organ-on-chip microphysiological systems, including skin-on-chip models for cosmetic and pharmaceutical compound testing. It is a direct technology and use-case peer to BioHive's organoid-based in vitro skin platform.
• StratiCELL: StratiCELL provides in vitro skin and tissue testing services for cosmetics and pharmaceutical R&D, including reconstructed human epidermis assays and efficacy/inflammation studies — closely matching BioHive's service-based GTM into dermo-cosmetic and pharma accounts.
• CellSystems: CellSystems supplies primary cells, 3D tissue models (including skin), and cell-based assay services to pharmaceutical and cosmetic R&D. It is a comparable European provider of in vitro skin and tissue models for compound testing.
• MatTek Life Sciences: MatTek produces reconstructed human epidermis and full-thickness skin tissue models (EpiDerm, EpiDermFT) used by cosmetics and pharmaceutical companies for irritation, toxicity, and efficacy testing — directly overlapping with BioHive's pharma and dermo-cosmetic in vitro skin model offering.

Broad incumbents

• BICO (CELLINK): BICO, parent of CELLINK, provides bioprinting platforms, reagents, and organoid tools for life-science R&D across multiple tissue types. It serves many of the same pharmaceutical and academic customers as BioHive but operates at much broader scale as a tools and consumables provider.
• Organovo: Organovo develops 3D bioprinted human tissues for preclinical research and drug discovery. It addresses a broader tissue portfolio than BioHive (not skin-only) but competes in the same general category of in vitro human tissue models for compound analysis.

Emerging players

• Poietis: Poietis develops laser-assisted 3D bioprinting of living tissues, with a specific focus on skin tissue for cosmetic and pharmaceutical testing. It is an emerging player with strong overlap to BioHive's skin-specific in vitro model value proposition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/biohive-innovations

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioHive